What is amycretin? Structure, research and status

Amycretin is a single investigational peptide that activates both GLP-1 and amylin receptors. Novo Nordisk developed it and now tests it in Phase 3 trials under the name zenagamtide.

Complete guide10 min read

Key takeaway

Amycretin is a Novo Nordisk peptide in Phase 3 development. In a 36-week study of 125 adults, mean weight in the highest group fell 24.3%, versus 1.1% on placebo [5]. Two 2026 Phase 2 reports in type 2 diabetes found HbA1c reductions versus placebo [6], [7]. Gastrointestinal events were the most common reported side effects.

At a glance

Article typeComplete guide
Regulatory statusIn clinical trials“Amycretin is not approved by the FDA for any use.” (this article)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited6 in this article · 6 across 1 article on Amycretin
Related productsIncretin analogs

Amycretin joins a modified GLP-1 sequence and an amylin receptor agonist in one 68-amino-acid chain. In 2025, the World Health Organization proposed zenagamtide as its international nonproprietary name [1]. Published human results come from two early studies and one Phase 2 diabetes trial reported in two papers. FDA has not approved it.

Quick answer: Amycretin is not approved by the FDA for any use. It is being tested in Phase 3 trials for obesity, type 2 diabetes, heart failure and cardiovascular risk. Research material sold under either name is not an approved medicine.

Vitrapep does not sell amycretin; this page is a reference summary of published research and regulatory information.

What is amycretin and how is it built?

Novo Nordisk scientists describe amycretin, code NNC0487-0111, as a unimolecular GLP-1 and amylin receptor agonist [3]. Unimolecular means one molecule carries both activities. Trial papers from 2026 use the WHO name zenagamtide and say the compound was formerly called amycretin [6].

The WHO entry describes three parts [1]. Positions 1 to 31 are a modified version of human GLP-1. Positions 32 to 35 are a linker of four glycine residues. Positions 36 to 68 are an artificial amylin receptor agonist, ending in an amide [1].

Aminoisobutyric acid near the start protects the chain from the enzyme DPP-4 [3]. An 18-carbon fatty diacid side chain binds reversibly to albumin, a blood protein, to extend half-life [3]. The amylin part is a calcitonin-based sequence with no disulfide bonds. The designers aimed for one molecule matching CagriSema's activity at both receptor types in cell tests [3]. PubChem holds substance records for zenagamtide but no computed compound record [2].

Table 1

What is amycretin and how is it built

PropertyAmycretin
Other namesZenagamtide (proposed INN, WHO List 133, 2025); NNC0487-0111 [1], [3]
ClassUnimolecular GLP-1 and amylin receptor agonist; also activates the calcitonin receptor [3], [6]
Structure68 amino acids: modified GLP-1, glycine linker, artificial amylin receptor agonist, C-terminal amide [1]
Key modificationsAminoisobutyric acid at position 2; fatty diacid side chain on the lysine at position 31 [1], [3]
Molecular formulaC343H550N94O116 [1], [3]
Molecular weight7,847 Da (average) [3]
CAS number3005889-81-3 [1]
FDA UNIIT2EA5S9XJ5 [2]
Development stagePhase 3 since February 24, 2026 (AMAZE 1)
US statusNot FDA-approved; no Drugs@FDA application as of November 18, 2026 [13]

How does amycretin work?

Amycretin acts on two hormone systems. GLP-1 is a gut hormone released after meals. Activation of its receptor raises glucose-dependent insulin release, slows stomach emptying and acts on appetite pathways (see what GLP-1 is).

Amylin is a 37-amino-acid hormone that pancreatic beta cells release together with insulin after a meal [3]. It acts on brain pathways that regulate food intake and energy balance [3]. Amylin receptors are pairs formed by the calcitonin receptor and one of three helper proteins called RAMPs [3]. Pramlintide, an amylin analog, was FDA-approved as Symlin in 2005 [13] (see the pramlintide complete guide).

Cell findings. Amycretin activated human, mouse and rat GLP-1, amylin and calcitonin receptors in cell-based tests [3]. Its activity at the human GLP-1 receptor was comparable with semaglutide's. It showed negligible activity at the related CGRP and adrenomedullin receptors [3].

Animal findings. In diet-induced obese rats, 21 days of amycretin cut energy intake by 47% and body weight by 18% compared with vehicle [3]. Energy expenditure was maintained. About 70% of the weight lost was fat mass [3]. Insulin sensitivity improved, and in obese mice amycretin reduced fat buildup in the liver [3]. All authors were Novo Nordisk employees, and animal results do not show the same effects in people.

CagriSema pursues the same two targets with two separate molecules (see the cagrilintide complete guide and the CagriSema trial summary).

What is amycretin being studied for?

On November 18, 2026, ClinicalTrials.gov listed 36 Novo Nordisk studies of the compound under its three names. Nineteen were Phase 3. Weight trials carry the acronym AMAZE, and type 2 diabetes trials carry the acronym AMBITION. Vitrapep's guide on how to find a peptide clinical trial explains registry statuses.

Table 2

What is amycretin being studied for

TrialPopulation and comparatorPlanned sizeStatus on November 18, 2026
AMAZE 1Adults with obesity; placebo1,150Recruiting
AMAZE 2Overweight or obesity with type 2 diabetes; placebo638Active, not recruiting
AMAZE 3 and 4Excess weight with obstructive sleep apnea300 eachRecruiting
AMAZE 5 and 6Excess weight with knee osteoarthritis400 eachRecruiting
AMAZE 7Adults with obesity; semaglutide650Recruiting
AMAZE 9Adults with obesity; tablet form; placebo950Recruiting
HF-POLARISHeart failure with preserved or mildly reduced ejection fraction and obesity; placebo5,610Recruiting
AMBIENCEAtherosclerotic cardiovascular disease with overweight or obesity; placebo8,500Not yet recruiting
AMBITION 7Type 2 diabetes with raised cardiovascular risk; insulin glargine1,778Recruiting

Weight trials measure the percentage change in body weight, at week 84 in AMAZE 1. AMBIENCE counts cardiovascular death, heart attack, stroke and heart failure events. AMBITION 7 tests whether HbA1c lowering is noninferior to insulin glargine at week 52. In November 2025, Novo Nordisk said it expected an extensive Phase 3 program across multiple indications in 2026 [10].

What did the key amycretin trials show?

Four peer-reviewed reports give full human results. Novo Nordisk funded all four, and company employees were among the authors [4], [5], [6], [7].

First human study. This trial (NCT05369390) tested a tablet form in 144 adults with overweight or obesity at one San Antonio site [4]. Its parts ran from a single dose up to 12 weeks. The primary endpoint was adverse events, and weight change was exploratory [4]. A 2026 review reports weight loss of up to 13.1% after 85 days [8].

Phase 1b/2a study. This trial (NCT06064006) tested an injectable form at the same center [5]. It randomized 125 adults: 101 to amycretin and 24 to placebo. Mean weight change at week 36 was -24.3% in the highest group versus -1.1% on placebo [5]. The shortest group showed -9.7% versus +2.0% at week 20 [5]. Each multiple-dose group had 16 to 34 participants on amycretin [8]. Many withdrew, a high proportion for reasons unrelated to adverse events [5].

Phase 2 in type 2 diabetes. One 36-week trial (NCT06542874) tested both forms at 83 sites in 11 countries [6], [7]. Adults had HbA1c of 7.0% to 10.0% on metformin, with or without an SGLT2 inhibitor. In the injectable arm, HbA1c fell 0.9 to 1.7 points from a mean baseline of 7.8% [6]. In the tablet arm, it fell 0.9 to 1.4 points, and all three dose levels differed significantly from placebo [7].

Table 3

What did the key amycretin trials show

TrialDesign and populationSize and lengthMain result
NCT05369390, Lancet 2025 [4]First-in-human, placebo-controlled; tablet form; adults with overweight or obesity144 adults; single dose up to 12 weeksPrimary: 364 adverse events in 89 participants (62%), all mild or moderate
NCT06064006, Lancet 2025 [5]Phase 1b/2a, placebo-controlled; injectable form; adults with overweight or obesity125 adults; 20 to 36 weeksWeight change -24.3% vs -1.1% with placebo at week 36 (highest group)
NCT06542874, Lancet 2026 [6]Phase 2, placebo-controlled, dose-finding; injectable form; type 2 diabetes262 adults; 36 weeksHbA1c difference vs placebo: -0.77 to -1.56 points
NCT06542874, Lancet 2026 [7]Phase 2, placebo-controlled, dose-finding; tablet form; type 2 diabetes186 adults; 36 weeksHbA1c difference vs placebo: -0.5 to -1.09 points

No head-to-head results exist yet. AMAZE 7 and AMAZE 8 compare amycretin with semaglutide.

What side effects have amycretin trials reported?

Amycretin has no FDA label, so no labeled adverse reactions or warnings exist. The data below come from published trials.

Table 4

What side effects have amycretin trials reported

TrialMost common adverse events reportedSerious adverse events and deaths
First human study [4]Gastrointestinal: 180 of 364 events (49%), reported by 72 of the 89 participants with any eventNo deaths; one diabetic ketoacidosis case described in a 2026 review [8]
Phase 1b/2a [5]Gastrointestinal, mostly mild to moderate and resolved by study endNot given in the abstract
Phase 2, injectable [6]Gastrointestinal, mostly mild to moderate21 of 261 (8%), including 3 on placebo; no deaths
Phase 2, tablet [7]Gastrointestinal: 26%, 41% and 47% across dose levels vs 23% on placebo7 of 186, all on amycretin; none on placebo; no deaths

In the first study, adverse events became more frequent at higher doses, and the highest single doses tested were not considered tolerable [4], [8].

Heart rate and calcium. The review reports heart rate increases in both early studies; in the tablet study they resolved during follow-up [8]. Both studies also recorded decreases in mean ionized calcium. In the injectable study, the drop resolved by 48 hours and was not clinically meaningful [8].

Diabetic ketoacidosis. One participant in the first study developed diabetic ketoacidosis about 1.5 months after his first dose [8]. He had no diabetes history and was later diagnosed with type 1 diabetes. A single case cannot show whether amycretin played a role.

The Ozempic label warns about acute pancreatitis and gallbladder disease (see what GLP-1 is). Published amycretin studies were too small and short to assess uncommon events like these.

What is the regulatory status of amycretin?

United States. Amycretin is not approved by the FDA for any use. openFDA lists no application under amycretin or zenagamtide [13]. FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, does not name amycretin [11].

That page says FDA has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide [11]. Those products carried false "for research purposes" or "not for human consumption" labels. FDA says they were sold for human use and may be harmful [11]. A research-use-only label does not make a product legal or safe for people (see research peptides and human-use risks).

Development status. Novo Nordisk describes zenagamtide as investigational and under study in tablet and injectable forms [9]. In June 2026, the company said it planned to begin Phase 3 diabetes trials in the second half of 2026 [9]. AMBITION 7 started on August 24, 2026, according to its registry record.

Sport. The 2026 WADA Prohibited List does not name amycretin, zenagamtide, GLP-1 or amylin [12]. Its S0 class bans, at all times, substances not covered elsewhere that lack current approval from any government health regulator for human therapeutic use [12]. WADA's examples include drugs under clinical development [12]. Vitrapep summarizes the 2026 WADA list for peptides.

What is still unknown about amycretin?

No Phase 3 trial has reported, and the earliest estimated primary completion dates fall in mid-2028. The four published reports included 717 participants, with no treatment period longer than 36 weeks [5], [6]. Both early studies ran at a single US center [4], [5].

The published abstracts do not report how much of the weight people lost was lean mass. The long-term meaning of the calcium and heart rate changes is unknown. Cardiovascular and heart failure outcomes will come from AMBIENCE and HF-POLARIS.

Frequently asked questions

Is amycretin a peptide?

Yes. It is a chain of 68 amino acids with an attached fatty acid side chain. It ends in an amide [1], [3].

Is amycretin the same as zenagamtide?

Yes. WHO proposed zenagamtide as the nonproprietary name in 2025. Trial papers from 2026 say zenagamtide was formerly called amycretin.

Is amycretin FDA-approved?

No. FDA has not approved it for any use. Its first Phase 3 trial began in February 2026, and none has reported results.

How is amycretin different from CagriSema?

CagriSema combines two separate molecules, cagrilintide and semaglutide. Amycretin carries GLP-1 and amylin receptor activity in a single molecule.

What side effects did amycretin trials report?

Gastrointestinal events were most common, and most were mild to moderate. Early studies also reported heart rate increases and decreases in blood calcium after dosing.

Is amycretin banned in sport?

The 2026 WADA Prohibited List does not name it. The list's S0 class covers substances with no governmental approval for human therapeutic use, including drugs in clinical development.

What to know now

  • Amycretin, now named zenagamtide, is a single 68-amino-acid peptide that activates GLP-1 and amylin receptors.
  • FDA has not approved it, and 19 Phase 3 trials were registered as of November 18, 2026.
  • Published trials reported weight loss in adults with obesity and HbA1c reductions in type 2 diabetes versus placebo.
  • Gastrointestinal events were the most common side effects in every published trial.

What we’re watching

  • First Phase 3 results from the AMAZE and AMBITION programs.
  • Head-to-head results against semaglutide from AMAZE 7 and AMAZE 8.
  • Outcome data from the HF-POLARIS heart failure trial and the AMBIENCE cardiovascular trial.

More for endocrine & metabolism

All 49 compounds for endocrine & metabolism

Sources: World Health Organization 2025, WHO Drug Information, 39; National Center for Biotechnology Information 2026; Kuhre 2025, eBioMedicine, 118; Gasiorek 2025, Lancet, 406; Dahl 2025, Lancet, 406; Mora 2026, Lancet, 408; Mora 2026, Lancet, 408; Panou 2026, Diabetes Therapy, 17; Novo Nordisk 2026; Novo Nordisk 2025; U.S. Food and Drug Administration 2026; World Anti-Doping Agency 2025; U.S. Food and Drug Administration 2026. All 13 citations

Back to the research library

References

  1. World Health Organization. (2025). International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN List 133 (zenagamtide). WHO Drug Information, 39(2). https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl133.pdf
  2. National Center for Biotechnology Information. (2026). PubChem substance record SID 518139431, zenagamtide. https://pubchem.ncbi.nlm.nih.gov/substance/518139431
  3. Kuhre, R. E., Ballarín-González, B., Brand, C. L., et al. (2025). The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats. eBioMedicine, 118, 105862. https://pubmed.ncbi.nlm.nih.gov/40706446/
  4. Gasiorek, A., Heydorn, A., Gabery, S., et al. (2025). Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. Lancet, 406(10499), 135-148. https://pubmed.ncbi.nlm.nih.gov/40550229/
  5. Dahl, K., Toubro, S., Dey, S., et al. (2025). Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet, 406(10499), 149-162. https://pubmed.ncbi.nlm.nih.gov/40550231/
  6. Mora, P., Aroda, V. R., Asong, M., et al. (2026). Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet, 408(10555), 621-635. https://pubmed.ncbi.nlm.nih.gov/42532080/
  7. Mora, P., Aroda, V. R., Asong, M., et al. (2026). Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet, 408(10555), 607-620. https://pubmed.ncbi.nlm.nih.gov/42532079/
  8. Panou, T., Gouveri, E., Popovic, D. S., & Papanas, N. (2026). New amylin-based agonists for the treatment of obesity and type 2 diabetes mellitus. Diabetes Therapy, 17(11), 1613-1638. https://pubmed.ncbi.nlm.nih.gov/42803913/
  9. Novo Nordisk. (2026, June 6). Novo Nordisk's investigational zenagamtide shows significant HbA1C reductions with up to 14.6% weight loss in adults with type 2 diabetes, presented at ADA 2026. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916559
  10. Novo Nordisk. (2025, November 25). Company announcement No 38/2025: Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916463
  11. U.S. Food and Drug Administration. (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  12. World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
  13. U.S. Food and Drug Administration. (2026). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm